A Nature Communications paper identified the m6A RNA demethylase ALKBH5 as a key maintainer of colorectal cancer stemness and chemoresistance and showed that ALKBH5 inhibition impairs tumor-initiating cell properties. The authors report pathway-level effects on RNA methylation that reduce stem-like behaviour and sensitize tumors to therapy in models. The work positions ALKBH5 as a candidate target for small molecules or oligonucleotide approaches aimed at overcoming relapse and resistance in colorectal cancer.